OTCMGBLP
Market cap4mUSD
Dec 02, Last price
0.15USD
Name
Global Pharmatech Inc
Chart & Performance
Profile
Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. The company's principal product line consists of XS CAPSULE (XIN-SHU) for the treatment of angina and other coronary disease; JUTAI SOFT CAPSULE, a dietary supplement; QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter drug product indicated for the treatment of hypertension and high serum cholesterol level; and YANREQING TABLET for the treatment of inflammation. It also manufactures and sells other proprietary drugs, generics, and dietary supplements used to treat symptoms ranging from headaches, coughing, and dry mouth to infections, and numbness of limbs. The company markets its products through distributors, such as wholesale companies and chain store representatives, as well as through its sales force. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | |
Income | |||
Revenues | 66 13.30% | 59 | |
Cost of revenue | 23 | 29 | |
Unusual Expense (Income) | |||
NOPBT | 44 | 29 | |
NOPBT Margin | 66.02% | 50.18% | |
Operating Taxes | (237) | ||
Tax Rate | |||
NOPAT | 44 | 29 | 237 |
Net income | (138) 559.39% | (21) -81.46% | (113) |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 119 | 340 | 64 |
BB yield | |||
Debt | |||
Debt current | 50 | ||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | (26) | 12 | |
Cash flow | |||
Cash from operating activities | (199) | 391 | (63) |
CAPEX | 199 | (229) | |
Cash from investing activities | 23 | (229) | |
Cash from financing activities | 165 | (131) | 64 |
FCF | 96 | 234 | |
Balance | |||
Cash | 21 | 33 | |
Long term investments | 5 | 5 | |
Excess cash | 23 | 35 | |
Stockholders' equity | (11,923) | (11,927) | (11,455) |
Invested Capital | 11,722 | 11,780 | 11,406 |
ROIC | 0.37% | 0.25% | 2.07% |
ROCE | |||
EV | |||
Common stock shares outstanding | 395,212 | 282,852 | 276,352 |
Price | |||
Market cap | |||
EV | |||
EBITDA | 44 | 29 | |
EV/EBITDA | |||
Interest | 35 | ||
Interest/NOPBT |